When a company raises money, either an initial public offering or follow-up offering, the offering may include DRs. The inclusion of DRs may broaden the shareholder base of the company.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

Ratio
DR:Ord
DR Price
Date
DR Price
(USD)
US / Non-US / Total DRs Placed US / Non-US / Total DR Captial Raised (USD) Pvtzn. Dep. Bank Industry Country Region
1:1 Jul 19, 2023 490.00 1,917,715
0
1,917,715
939,680,350
0
939,680,350
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 Mar 28, 2022 300.00 1,783,701
0
1,783,701
535,110,300
0
535,110,300
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 Feb 03, 2021 320.00 2,076,750
0
2,076,750
664,560,000
0
664,560,000
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 May 27, 2020 205.00 3,132,915
0
3,132,915
642,247,575
0
642,247,575
-- BK Pharma. & Biotech. Netherlands Continental Europe
1:1 Nov 12, 2019 121.00 2,010,057
0
2,010,057
243,216,897
0
243,216,897
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 Sep 18, 2018 86.50 3,475,000
0
3,475,000
300,587,500
0
300,587,500
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 Dec 14, 2017 52.00 5,106,000
0
5,106,000
265,512,000
0
265,512,000
N BK Pharma. & Biotech. Netherlands Continental Europe
1:1 May 17, 2017 17.00 6,744,750
0
6,744,750
114,660,750
0
114,660,750
N BK Pharma. & Biotech. Netherlands Continental Europe

Powered by FactSet Research Systems Inc.